Noncanonical matrix metalloprotease-1-protease-activated receptor-1 signaling triggers vascular smooth muscle cell dedifferentiation and arterial stenosis

Journal of Biological Chemistry

Volumn 288, Issue 32, 2013, Pages 23105-23115

  Austin, Karyn M ^a,b   Nguyen, Nga ^a,b   Javid, Golrokh ^a   Covic, Lidija ^a,b   Kuliopulos, Athan ^a,b  

^a TUFTS UNIVERSITY   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTERIAL STENOSIS; RECEPTOR-1; VASCULAR INJURY; VASCULAR SMOOTH MUSCLE CELLS;

BIOCHEMISTRY; BIOLOGY;

ENZYMES;

GUANINE NUCLEOTIDE BINDING PROTEIN; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE INHIBITOR; PROTEINASE ACTIVATED RECEPTOR 1; THROMBIN; THROMBIN INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INTIMA PROLIFERATION; ARTERY OCCLUSION; ARTICLE; CAROTID ARTERY INJURY; CELL DEDIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; ENDOCYTOSIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MALE; MORPHOMETRICS; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE;

CARDIOVASCULAR DISEASE; CELL DIFFERENTIATION; MATRIX METALLOPROTEINASE (MMP); PAR1; SMOOTH MUSCLE; THROMBIN;

ANIMALS; CAROTID STENOSIS; CELL DEDIFFERENTIATION; CELL LINE; GENE EXPRESSION REGULATION; HUMANS; HYPERPLASIA; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 13; MICE; MUSCLE CONTRACTION; MYOCYTES, SMOOTH MUSCLE; PROTEASE INHIBITORS; RECEPTOR, PAR-1; SIGNAL TRANSDUCTION; TUNICA INTIMA;

EID: 84881461152     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M113.467019     Document Type: Article

References (50)

1. Heidenreich, P. A., Trogdon, J. G., Khavjou, O. A., Butler, J., Dracup, K., Ezekowitz, M. D., Finkelstein, E. A., Hong, Y., Johnston, S. C., Khera, A., Lloyd-Jones, D. M., Nelson, S. A., Nichol, G., Orenstein, D., Wilson, P. W., and Woo, Y. J. (2011) Forecasting the future of cardiovascular disease in the United States. A policy statement from the American Heart Association. Circulation 123, 933-944
2. Stone, G. W., Maehara, A., Lansky, A. J., de Bruyne, B., Cristea, E., Mintz, G. S., Mehran, R., McPherson, J., Farhat, N., Marso, S. P., Parise, H., Templin, B., White, R., Zhang, Z., and Serruys, P. W. (2011) A prospective natural-history study of coronary atherosclerosis. N. Engl. J. Med. 364, 226-235
3. Doran, A. C., Meller, N., and McNamara, C. A. (2008) Role of smooth muscle cells in the initiation and early progression of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 28, 812-819
4. Owens, G. K., Kumar, M. S., and Wamhoff, B. R. (2004) Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol. Rev. 84, 767-801
5. Smyth, S. S., Pathak, A., and Stouffer, G. A. (2002) In-stent restenosis. More fuel for the fire. Am. Heart J. 144, 577-579
6. Zhang, P., Gruber, A., Kasuda, S., Kimmelstiel, C., O'Callaghan, K., Cox, D. H., Bohm, A., Baleja, J. D., Covic, L., and Kuliopulos, A. (2012) Suppression of arterial thrombosis without affecting hemostatic parameters with a cell-penetrating PAR1 pepducin. Circulation 126, 83-91
7. Sevigny, L. M., Austin, K. M., Zhang, P., Kasuda, S., Koukos, G., Sharifi, S., Covic, L., and Kuliopulos, A. (2011) Protease-activated receptor-2 modulates protease-activated receptor-1-driven neointimal hyperplasia. Arterioscler. Thromb. Vasc. Biol. 31, e100-106
8. Leger, A. J., Covic, L., and Kuliopulos, A. (2006) Protease-activated receptors in cardiovascular diseases. Circulation 114, 1070-1077
9. Cheung, W. M., D'Andrea, M. R., Andrade-Gordon, P., and Damiano, B. P. (1999) Altered vascular injury responses in mice deficient in proteaseactivated receptor-1. Arterioscler. Thromb. Vasc. Biol. 19, 3014-3024
10. Burchenal, J. E., Marks, D. S., Tift Mann, J., Schweiger, M. J., Rothman, M. T., Ganz, P., Adelman, B., and Bittl, J. A. (1998) Effect of direct thrombin inhibition with Bivalirudin (Hirulog) on restenosis after coronary angioplasty. Am. J. Cardiol. 82, 511-515
11. Preisack, M. B., Baildon, R., Eschenfelder, V., Foley, D., Garcia, E., Kaltenbach, M., Meisner, C., Selbmann, H. K., Serruys, P. W., Shiu, M. F., Sujatta, M., Bonan, R., and Karsch, K. R. (1997) [Low molecular weight heparin, reviparin, after PTCA. Results of a randomized double-blind, standard heparin and placebo controlled multicenter study (REDUCE) Study]. Z. Kardiol. 86, 581-591
12. Boire, A., Covic, L., Agarwal, A., Jacques, S., Sherifi, S., and Kuliopulos, A. (2005) PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell 120, 303-313
13. Newby, A. C. (2012) Matrix metalloproteinase inhibition therapy for vascular diseases. Vascul. Pharmacol. 56, 232-244
14. Butler, G. S., and Overall, C. M. (2009) Proteomic identification of multitasking proteins in unexpected locations complicates drug targeting. Nat. Rev. Drug Discov. 8, 935-948
15. Andrade-Gordon, P., Derian, C. K., Maryanoff, B. E., Zhang, H. C., Addo, M. F., Cheung, W., Damiano, B. P., D'Andrea, M. R., Darrow, A. L., de Garavilla, L., Eckardt, A. J., Giardino, E. C., Haertlein, B. J., and McComsey, D. F. (2001) Administration of a potent antagonist of protease-activated receptor-1 (PAR-1) attenuates vascular restenosis following balloon angioplasty in rats. J. Pharmacol. Exp. Ther. 298, 34-42
16. Galis, Z. S., Sukhova, G. K., Lark, M. W., and Libby, P. (1994) Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J. Clin. Invest. 94, 2493-2503
17. Nikkari, S. T., O'Brien, K. D., Ferguson, M., Hatsukami, T., Welgus, H. G., Alpers, C. E., and Clowes, A. W. (1995) Interstitial collagenase (MMP-1) expression in human carotid atherosclerosis. Circulation 92, 1393-1398
18. Sukhova, G. K., Schönbeck, U., Rabkin, E., Schoen, F. J., Poole, A. R., Billinghurst, R. C., and Libby, P. (1999) Evidence for increased collagenolysis by interstitial collagenases-1 and-3 in vulnerable human atheromatous plaques. Circulation 99, 2503-2509
19. Lehrke, M., Greif, M., Broedl, U. C., Lebherz, C., Laubender, R. P., Becker, A., von Ziegler, F., Tittus, J., Reiser, M., Becker, C., Göke, B., Steinbeck, G., Leber, A. W., and Parhofer, K. G. (2009) MMP-1 serum levels predict coronary atherosclerosis in humans. Cardiovasc. Diabetol. 8, 50-59
20. Wu, Y. W., Yang, W. S., Chen, M. F., Lee, B. C., Hung, C. S., Liu, Y. C., Jeng, J. S., Huang, P. J., and Kao, H. L. (2008) High serum level of matrix metalloproteinase-1 and its rapid surge after intervention in patients with significant carotid atherosclerosis. J. Formos. Med. Assoc. 107, 93-98
21. Lee, R. T., Schoen, F. J., Loree, H. M., Lark, M. W., and Libby, P. (1996) Circumferential stress and matrix metalloproteinase 1 in human coronary atherosclerosis. Implications for plaque rupture. Arterioscler. Thromb. Vasc. Biol. 16, 1070-1073
22. Zhang, J., Nie, L., Razavian, M., Ahmed, M., Dobrucki, L. W., Asadi, A., Edwards, D. S., Azure, M., Sinusas, A. J., and Sadeghi, M. M. (2008) Molecular imaging of activated matrix metalloproteinases in vascular remodeling. Circulation 118, 1953-1960
23. Tressel, S. L., Kaneider, N. C., Kasuda, S., Foley, C., Koukos, G., Austin, K., Agarwal, A., Covic, L., Opal, S. M., and Kuliopulos, A. (2011) A matrix metalloprotease-PAR1 system regulates vascular integrity, systemic inflammation and death in sepsis. EMBO Mol. Med. 3, 370-384
24. Kimmelstiel, C., Zhang, P., Kapur, N. K., Weintraub, A., Krishnamurthy, B., Castaneda, V., Covic, L., and Kuliopulos, A. (2011) Bivalirudin is a dual inhibitor of thrombin and collagen-dependent platelet activation in patients undergoing percutaneous coronary intervention. Circ. Cardiovasc. Interv. 4, 171-179
25. Leger, A. J., Jacques, S. L., Badar, J., Kaneider, N. C., Derian, C. K., Andrade-Gordon, P., Covic, L., and Kuliopulos, A. (2006) Blocking the protease-activated receptor 1-4 heterodimer in platelet-mediated thrombosis. Circulation 113, 1244-1254
26. Nelken, N. A., Soifer, S. J., O'Keefe, J., Vu, T. K., Charo, I. F., and Coughlin, S. R. (1992) Thrombin receptor expression in normal and atherosclerotic human arteries. J. Clin. Invest. 90, 1614-1621
27. Foley, C. J., Luo, C., O'Callaghan, K., Hinds, P. W., Covic, L., and Kuliopulos, A. (2012) Matrix metalloprotease-1a promotes tumorigenesis and metastasis. J. Biol. Chem. 287, 24330-24338
28. Pfaffen, S., Hemmerle, T., Weber, M., and Neri, D. (2010) Isolation and characterization of human monoclonal antibodies specific to MMP-1A, MMP-2 and MMP-3. Exp. Cell Res. 316, 836-847
29. Pfaffen, S., Frey, K., Stutz, I., Roesli, C., and Neri, D. (2010) Tumourtargeting properties of antibodies specific to MMP-1A, MMP-2 and MMP-3. Eur. J. Nucl. Med. Mol. Imaging 37, 1559-1565
30. Kamath, L., Meydani, A., Foss, F., and Kuliopulos, A. (2001) Signaling from protease-activated receptor-1 inhibits migration and invasion of breast cancer cells. Cancer Res. 61, 5933-5940
31. Trivedi, V., Boire, A., Tchernychev, B., Kaneider, N. C., Leger, A. J., O'Callaghan, K., Covic, L., and Kuliopulos, A. (2009) Platelet matrix metalloprotease-1 mediates thrombogenesis by activating PAR1 at a cryptic ligand site. Cell 137, 332-343
32. Trejo, J. (2003) Protease-activated receptors. New concepts in regulation ofGprotein-coupled receptor signaling and trafficking. J. Pharmacol. Exp. Ther. 307, 437-442
33. Gomez, D., and Owens, G. K. (2012) Smooth muscle cell phenotypic switching in atherosclerosis. Cardiovasc. Res. 95, 156-164
34. Gerthoffer, W. T. (2005) Actin cytoskeletal dynamics in smooth muscle contraction. Can. J. Physiol. Pharmacol. 83, 851-856
35. Parmacek, M. S. (2008) Myocardin. Dominant driver of the smooth muscle cell contractile phenotype. Arterioscler. Thromb. Vasc. Biol. 28, 1416-1417
36. Long, X., Bell, R. D., Gerthoffer, W. T., Zlokovic, B. V., and Miano, J. M. (2008) Myocardin is sufficient for a smooth muscle-like contractile phenotype. Arterioscler. Thromb. Vasc. Biol. 28, 1505-1510
37. Komatsu, M., and Ruoslahti, E. (2005) R-Ras is a global regulator of vascular regeneration that suppresses intimal hyperplasia and tumor angiogenesis. Nat. Med. 11, 1346-1350
38. Hatziapostolou, M., Koukos, G., Polytarchou, C., Kottakis, F., Serebrennikova, O., Kuliopulos, A., and Tsichlis, P. N. (2011) Tumor progression locus 2 mediates signal-induced increases in cytoplasmic calcium and cell migration. Sci. Signal. 4, ra55
39. Eckart, R. E., Uyehara, C. F., Shry, E. A., Furgerson, J. L., and Krasuski, R. A. (2004) Matrix metalloproteinases in patients with myocardial infarction and percutaneous revascularization. J. Interv. Cardiol. 17, 27-31
40. Pearce, E., Tregouet, D. A., SamnegArd, A., Morgan, A. R., Cox, C., Hamsten, A., Eriksson, P., and Ye, S. (2005) Haplotype effect of the matrix metalloproteinase-1 gene on risk of myocardial infarction. Circ. Res. 97, 1070-1076
41. Gaubatz, J. W., Ballantyne, C. M., Wasserman, B. A., He, M., Chambless, L. E., Boerwinkle, E., and Hoogeveen, R. C. (2010) Association of circulating matrix metalloproteinases with carotid artery characteristics. The Atherosclerosis Risk in Communities Carotid MRI Study. Arterioscler. Thromb. Vasc. Biol. 30, 1034-1042
42. Navarese, E. P., Kubica, J., and Gurbel, P. A. (2011) Sirolimus or paclitaxel drug eluting stent in left main disease. The winner is Int. J. Cardiol. 152, 387
43. Zempo, N., Koyama, N., Kenagy, R. D., Lea, H. J., and Clowes, A. W. (1996) Regulation of vascular smooth muscle cell migration and proliferation in vitro and in injured rat arteries by a synthetic matrix metalloproteinase inhibitor. Arterioscler. Thromb. Vasc. Biol. 16, 28-33
44. de Smet, B. J., de Kleijn, D., Hanemaaijer, R., Verheijen, J. H., Robertus, L., van Der Helm, Y. J., Borst, C., and Post, M. J. (2000) Metalloproteinase inhibition reduces constrictive arterial remodeling after balloon angioplasty. A study in the atherosclerotic Yucatan micropig. Circulation 101, 2962-2967
45. Peterson, J. T. (2006) The importance of estimating the therapeutic index in the development of matrix metalloproteinase inhibitors. Cardiovasc. Res. 69, 677-687
46. Gurbel, P. A., Jeong, Y. H., and Tantry, U. S. (2011) Vorapaxar. A novel protease-activated receptor-1 inhibitor. Expert. Opin. Investig. Drugs 20, 1445-1453
47. Tricoci, P., Huang, Z., Held, C., Moliterno, D. J., Armstrong, P. W., Van de Werf, F., White, H. D., Aylward, P. E., Wallentin, L., Chen, E., Lokhnygina, Y., Pei, J., Leonardi, S., Rorick, T. L., Kilian, A. M., Jennings, L. H., Ambrosio, G., Bode, C., Cequier, A., Cornel, J. H., Diaz, R., Erkan, A., Huber, K., Hudson, M. P., Jiang, L., Jukema, J. W., Lewis, B. S., Lincoff, A. M., Montalescot, G., Nicolau, J. C., Ogawa, H., Pfisterer, M., Prieto, J. C., Ruzyllo, W., Sinnaeve, P. R., Storey, R. F., Valgimigli, M., Whellan, D. J., Widimsky, P., Strony, J., Harrington, R. A., and Mahaffey, K. W. (2012) Thrombinreceptor antagonist vorapaxar in acute coronary syndromes. N. Engl. J. Med. 366, 20-33
48. Adam, S. S., McDuffie, J. R., Ortel, T. L., and Williams, J. W., Jr. (2012) Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism. A systematic review. Ann. Intern. Med. 157, 796-807
49. Jaffré, F., Friedman, A. E., Hu, Z., Mackman, N., and Blaxall, B. C. (2012)-Adrenergic receptor stimulation transactivates protease-activated receptor 1 via matrix metalloproteinase 13 in cardiac cells. Circulation 125, 2993-3003
50. Peeters, W., Moll, F. L., Vink, A., van der Spek, P. J., de Kleijn, D. P., de Vries, J. P., Verheijen, J. H., Newby, A. C., and Pasterkamp, G. (2011) Collagenase matrix metalloproteinase-8 expressed in atherosclerotic carotid plaques is associated with systemic cardiovascular outcome. Eur. Heart J. 32, 2314-2325